VANCOUVER, Aug. 4 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced the launch of a series of new, proprietary Quill(TM) SRS product codes specifically designed for laparoscopic, or minimally invasive, gynecology procedures, including hysterectomies and myomectomies. In 2008, there were approximately 750,000 hysterectomies performed in the United States of which approximately 130,000 were performed laparoscopically. In addition, there were approximately 72,000 myomectomies performed in the United States to remove uterine fibroid tumors. Management estimates 6-8% annual growth in laparoscopically assisted hysterectomies through 2014.
